AbbVie presents positive investigational Navitoclax combination data in Phase 2 study

AbbVie (NYSE: ABBV) announced new data from a Phase 2 trial of navitoclax in combination with ruxolitinib in patients with myelofibrosis. The results were presented at the American Association for Cancer Research annual meeting (AACR 2022, abstract #LB108). Navitoclax is an investigational, first-in-class, oral BCL-XL/BCL-2 inhibitor that is designed to activate programmed cell death (apoptosis) in cancer cells. Navitoclax and its safety and efficacy are under evaluation as part of ongoing Phase 2 and registrational Phase 3 studies.

“Myelofibrosis is a cancer that originates in the bone marrow, leading to fibrosis. Currently, available therapies do not address the underlying disease biology and have not shown a consistent effect on both biomarkers of disease modification and overall survival. Disease control with reversal of bone marrow fibrosis is a key objective for improving patient outcomes,” said Mohamed Zaki, M.D., Ph.D., vice president and global head of oncology clinical development at AbbVie. “That’s why we are especially pleased about these early results of navitoclax in combination with ruxolitinib that indicate its novel mechanism of action of inducing cell death may cause reversal of bone marrow fibrosis and extend survival for patients who respond to treatment.”

JPMorgan Multi-Asset Growth & Income plc (LON:MATE) combines sustainable income and capital growth from globally diversified investments. The Investment Trust’s multi-asset investing approach aims to achieve a long-term total return of 6% per annum and an initial annual dividend of 4% paid quarterly. This provides an attractive income investing and capital growth opportunity while seeking to maintain lower levels of portfolio volatility than a traditional equity portfolio.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

Analog Devices sees growth accelerating

Analog Devices expects annual revenue growth to average 7% to 10% over the next five years, the chip maker told analysts at a meeting Tuesday morning at the company’s headquarters near Boston. As the name implies, Analog

US FDA approves new Bristol Myers cancer immunotherapy

Bristol Myers Squibb Co said on Friday that U.S. regulators approved the first drug in a new class of cancer immunotherapies as an initial treatment for advanced melanoma, the deadliest form of skin cancer. The company

Procter & Gamble-owned Pantene partners with impressive female collective

THE WHAT? Procter & Gamble-owned Pantene has teamed up with ‘impressive, strong, modern, multi-hyphenate women’ to form the new Pantene Conditioner Collective. THE DETAILS Partners of the collective include Chloe Fineman, who features on Saturday Night Live and Dickinson, comedian Meg

Procter & Gamble’s sales jump

Shoppers shrugged off rising prices last year on products like Pampers diapers and Charmin toilet paper, Procter & Gamble said on Wednesday in announcing a jump in its second-quarter earnings. The consumer goods giant reported that

Abbvie looks to crack the cystic fibrosis code

When it comes to cystic fibrosis Vertex is the undisputed heavyweight, but this has not stopped other groups from taking it on. Abbvie is the latest challenger, and data due this quarter could give clues about

Italy to receive 40,000 Merck antiviral drug doses next week

Italy will receive around 40,000 doses of Merck & Co’s (MRK.N) COVID-19 antiviral drug next week, which will add to nearly 12,000 already distributed to hospitals, the special COVID-19 commissioner said on Sunday. “They are intended